Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$178.7M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
607.93%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$72.74M
Q3 2024
Cash
Q3 2024
P/E
-0.5598
Nov 29, 2024 EST
Free Cash Flow
-$105.5M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Selling, General & Admin $45.15M $57.35M $75.15M $51.52M $29.56M $12.43M $3.750M $2.390M
YoY Change -21.27% -23.69% 45.86% 74.29% 137.81% 231.47% 56.9%
% of Gross Profit
Research & Development $150.9M $265.1M $196.3M $105.5M $61.86M $33.29M $18.51M $14.67M
YoY Change -43.07% 35.02% 86.03% 70.61% 85.83% 79.87% 26.13%
% of Gross Profit
Depreciation & Amortization $6.141M $7.100M $2.300M $1.500M $1.500M $200.0K $200.0K $148.0K
YoY Change -13.51% 208.7% 53.33% 0.0% 650.0% 0.0% 35.14%
% of Gross Profit
Operating Expenses $196.1M $322.4M $271.5M $157.1M $91.42M $45.72M $22.25M $17.06M
YoY Change -39.19% 18.77% 72.85% 71.8% 99.95% 105.45% 30.45%
Operating Profit -$196.1M -$322.4M -$271.5M -$157.1M -$91.42M -$45.72M -$22.25M -$17.06M
YoY Change -39.19% 18.77% 72.85% 71.8% 99.95% 105.45% 30.45%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Interest Expense $10.35M $3.673M $377.0K $4.313M $6.201M $2.375M -$1.302M -$51.00K
YoY Change 181.7% 874.27% -91.26% -30.45% 161.09% -282.41% 2452.94%
% of Operating Profit
Other Income/Expense, Net $8.000K -$1.196M $1.238M -$736.0K -$155.0K -$192.0K -$287.0K $11.00K
YoY Change -100.67% -196.61% -268.21% 374.84% -19.27% -33.1% -2709.09%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Pretax Income -$185.7M -$320.0M -$269.9M -$153.5M -$85.37M -$43.54M -$23.84M -$17.10M
YoY Change -41.96% 18.56% 75.83% 79.78% 96.09% 82.6% 39.43%
Income Tax $0.00 $0.00 -$291.0K $0.00
% Of Pretax Income
Net Earnings -$185.7M -$320.0M -$269.9M -$153.5M -$85.37M -$43.54M -$23.55M -$17.10M
YoY Change -41.96% 18.56% 75.83% 79.78% 96.09% 84.86% 37.73%
Net Earnings / Revenue
Basic Earnings Per Share -$2.14 -$5.06 -$5.01 -$3.10
Diluted Earnings Per Share -$2.14 -$5.06 -$5.013M -$3.101M -$1.889M -$1.010M -$581.9K -$422.5K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Cash & Short-Term Investments $170.8M $279.8M $424.2M $659.0M $495.9M $178.9M $85.20M $13.40M
YoY Change -38.96% -34.05% -35.62% 32.89% 177.19% 109.98% 535.82%
Cash & Equivalents $66.44M $87.22M $152.8M $207.2M $38.40M $33.70M $85.20M $13.40M
Short-Term Investments $104.4M $192.6M $271.4M $451.8M $457.5M $145.2M
Other Short-Term Assets $9.095M $29.06M $27.34M $10.30M $4.000M $2.700M $1.000M $200.0K
YoY Change -68.7% 6.27% 165.47% 157.5% 48.15% 170.0% 400.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $179.9M $308.8M $451.6M $669.3M $499.9M $181.6M $86.20M $13.60M
YoY Change -41.75% -31.61% -32.53% 33.89% 175.28% 110.67% 533.82%
Property, Plant & Equipment $57.51M $69.37M $74.81M $48.10M $14.20M $8.800M $400.0K $300.0K
YoY Change -17.1% -7.27% 55.52% 238.73% 61.36% 2100.0% 33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.216M $8.208M $8.436M $2.300M $2.800M $800.0K $300.0K $300.0K
YoY Change -24.27% -2.7% 266.78% -17.86% 250.0% 166.67% 0.0%
Total Long-Term Assets $63.72M $77.58M $83.24M $50.30M $17.00M $9.700M $800.0K $600.0K
YoY Change -17.86% -6.81% 65.49% 195.88% 75.26% 1112.5% 33.33%
Total Assets $243.6M $386.4M $534.8M $719.6M $516.9M $191.3M $87.00M $14.20M
YoY Change
Accounts Payable $1.764M $4.832M $13.69M $14.00M $6.000M $2.100M $1.700M $1.000M
YoY Change -63.49% -64.71% -2.2% 133.33% 185.71% 23.53% 70.0%
Accrued Expenses $34.19M $24.15M $21.70M $8.400M $7.000M $3.000M $1.100M $1.500M
YoY Change 41.56% 11.27% 158.37% 20.0% 133.33% 172.73% -26.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.58M $30.04M $40.25M $22.50M $13.10M $5.300M $2.800M $2.500M
YoY Change 21.77% -25.37% 78.88% 71.76% 147.17% 89.29% 12.0%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $5.000M
YoY Change -100.0%
Other Long-Term Liabilities $38.22M $45.95M $49.10M $42.80M $8.100M $2.000M $0.00 $100.0K
YoY Change -16.83% -6.42% 14.72% 428.4% 305.0% -100.0%
Total Long-Term Liabilities $38.22M $45.95M $49.10M $42.80M $8.100M $2.000M $0.00 $5.100M
YoY Change -16.83% -6.42% 14.72% 428.4% 305.0% -100.0%
Total Liabilities $74.79M $75.99M $89.35M $65.20M $21.20M $7.300M $2.800M $7.600M
YoY Change -1.57% -14.95% 37.04% 207.55% 190.41% 160.71% -63.16%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Basic Shares Outstanding 86.80M 63.28M 53.83M 49.49M
Diluted Shares Outstanding 86.80M 63.28M 53.83M 49.49M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $100.06 Million

About Allakos Inc.

Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in San Carlos, California and currently employs 131 full-time employees. The company went IPO on 2018-07-19. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The firm is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.

Industry: Pharmaceutical Preparations Peers: 2seventy bio, Inc. ADMA BIOLOGICS, INC. Alaunos Therapeutics, Inc. Stoke Therapeutics, Inc. Entrada Therapeutics, Inc. G1 Therapeutics, Inc. Imago BioSciences, Inc. PRECIGEN, INC.